26 Life Sciences Report – Diagnostics “The new BeCAT research building implements a new research concept and, thanks to the good infrastructure of medical institutions in Berlin, enables the translation of scientific research, technological development and clinical application testing of ATMPs. The research initiative RESTORE will also advance research in the field of ATMPs throughout Europe and will help making our vision of healing patients instead of treating them become a little more reality.” © BCRT Prof. Petra Reinke Director, Member of the Steering Committee & Lead Scientist, Head of Research and Development (R&D), Berlin Center for Advanced Therapies, Charité – Universitätsmedizin Berlin tion and dispensing technology – opening up new dimensions for cell line development and single cell sequencing. Partnerships play an important role in their activities, the relationships to the scientific, academic and business communities are very strong. Transfer into clinics With the Charité – Universitätsmedizin Berlin, one of Europe‘s largest university hospitals with more than 35,000 beds and a wide spectrum of outstanding basic research, the region offers broad access to a patient collective of urban and rural population of about 180 ethnicities for implementing clinical trials to validate biomarkers. The Charité Research Organisation allows researchers to access a large group of patients in the German capital region for clinical trials. It provides the capabilities and collaborations that modern translational, experimental and exploratory clinical development groups are looking for. Labor Berlin, one of the largest clinical laboratories in Europe, combines the expertise of the Charité and Vivantes laboratories and offers complete solutions for any type of laboratory diagnostics for the diagnostics industry. With the new BeCAT research building - Berlin Center for Advanced Therapies – another state-of-the-art center is being built at the Charité Campus Virchow, which covers everything from basic research and technology development research to clinical trials. Numerous research groups from different fields are working on new therapeutic options, e.g. the development of cell-based products for endogenous regeneration, tissue engineering, gene therapeutics and immunotherapeutics as tumour therapy for diseases with high clinical demand. The BeCAT also includes a GMP laboratory unit to enable the production of all ATMP classes. Prof. Petra Reinke was appointed founding director of the center. She and her team of researchers are working on new therapeutic approaches for incipient and chronically manifested renal insufficiency. Prof. Igor Sauer is working on improving the de- and re-cellularisation of the liver as part of the NeoOrgan project in order to prevent tissue rejection as far as possible in the future. For BeCAT, additional new cellbased approaches with pro-regenerative and anti-inflammatory capacity for improved regeneration after partial liver resection are being developed. Prof. Petra Reinke and Prof. Hans-Dieter Volk from the BCRT coordinate the innovation project RESTORE, which is funded by the Horizon 2020 program. It supports the development and application of novel therapies and pursues the goal of transferring these novel therapies into everyday life. However, RESTORE is not only about research and development of these technologies, but also about education and training of different expert groups.
Life Sciences Report – Diagnostics 27 Health by Advanced Therapies Advanced therapies are one of the most recent and significant advances in medicine. They include gene and cell therapies and tissue-engineering approaches to not only treat disease symptoms, but to potentially provide a cure for otherwise incurable chronic diseases. A growing number of these advanced therapies are now reaching patients, transforming not just the lives of people afflicted with chronic diseases, but the lives of their families too. However, to make these innovative therapeutic strategies available to millions of patients, there are multiple challenges to overcome, from conceptual and technical hurdles through to special manufacturing issues and new payment models. We at RESTORE want to make these treatments options available to patients as a standard of care across Europe. We believe that Europe provides an optimal scientific ecosystem for such a large and concerted interdisciplinary effort, with excellent science, sound infrastructure and diverse funding opportunities. RESTORE is a network of over 300 research institutes, companies, consortia and non-profit organizations from Europe and beyond, which is managed by ten European partners and coordinated by the BCRT and BeCAT in Berlin. We are working on the “Advanced Therapies Roadmap for Horizon Europe” to make the vision of bringing Advanced Therapies to patients around the world a reality, and to build a European infrastructure to support and enable this vision. For more information, for to get involved, you can follow us on twitter.com/RESTOREhorizon www.facebook.com/RESTOREhorizon www.linkedin.com/company/restore-horizon and tag us @RESTOREhorizon www.restore-horizon.eu This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 820292.